190 related articles for article (PubMed ID: 17182760)
1. Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.
Chiba-Mizutani T; Miura H; Matsuda M; Matsuda Z; Yokomaku Y; Miyauchi K; Nishizawa M; Yamamoto N; Sugiura W
J Clin Microbiol; 2007 Feb; 45(2):477-87. PubMed ID: 17182760
[TBL] [Abstract][Full Text] [Related]
2. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
Miyake H; Iizawa Y; Baba M
J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
[TBL] [Abstract][Full Text] [Related]
3. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.
Spenlehauer C; Gordon CA; Trkola A; Moore JP
Virology; 2001 Feb; 280(2):292-300. PubMed ID: 11162843
[TBL] [Abstract][Full Text] [Related]
4. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
[TBL] [Abstract][Full Text] [Related]
5. A novel dual luciferase assay for the simultaneous monitoring of HIV infection and cell viability.
Mitsuki YY; Yamamoto T; Mizukoshi F; Momota M; Terahara K; Yoshimura K; Harada S; Tsunetsugu-Yokota Y
J Virol Methods; 2016 May; 231():25-33. PubMed ID: 26898957
[TBL] [Abstract][Full Text] [Related]
6. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5).
Hachiya A; Aizawa-Matsuoka S; Tanaka M; Takahashi Y; Ida S; Gatanaga H; Hirabayashi Y; Kojima A; Tatsumi M; Oka S
Antimicrob Agents Chemother; 2001 Feb; 45(2):495-501. PubMed ID: 11158746
[TBL] [Abstract][Full Text] [Related]
7. A potential in vitro and in vivo anti-HIV drug screening system for Chinese herbal medicines.
Feng L; Wang L; Ma YY; Li M; Zhao GQ
Phytother Res; 2012 Jun; 26(6):899-907. PubMed ID: 22852142
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1.
Baba M; Miyake H; Okamoto M; Iizawa Y; Okonogi K
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):935-41. PubMed ID: 10890354
[TBL] [Abstract][Full Text] [Related]
10. A novel dual-luciferase assay for anti-HIV drug screening based on the CCR5/CXCR4 promoters.
Feng L; Lu W; Ma Y; Guo W; Wang Y; Sun Q; Wu J; Zhao G; Zhang X
J Virol Methods; 2018 Jun; 256():17-23. PubMed ID: 29481882
[TBL] [Abstract][Full Text] [Related]
11. A novel colorimetric assay for CXCR4 and CCR5 tropic human immunodeficiency viruses.
Kajiwara K; Kodama E; Matsuoka M
Antivir Chem Chemother; 2006; 17(4):215-23. PubMed ID: 17066899
[TBL] [Abstract][Full Text] [Related]
12. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4.
BouHamdan M; Strayer DS; Wei D; Mukhtar M; Duan LX; Hoxie J; Pomerantz RJ
Gene Ther; 2001 Mar; 8(5):408-18. PubMed ID: 11313818
[TBL] [Abstract][Full Text] [Related]
14. Determination of HIV-1 infectivity by lymphocytic cell lines with integrated luciferase gene.
Nagao T; Yoshida A; Sakurai A; Piroozmand A; Jere A; Fujita M; Uchiyama T; Adachi A
Int J Mol Med; 2004 Dec; 14(6):1073-6. PubMed ID: 15547676
[TBL] [Abstract][Full Text] [Related]
15. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
[TBL] [Abstract][Full Text] [Related]
16. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Blanco J; Barretina J; Clotet B; Esté JA
J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 replication in CD4+ T cell lines: the effects of adaptation on co-receptor use, tropism, and accessory gene function.
Dejucq N
J Leukoc Biol; 2000 Sep; 68(3):331-7. PubMed ID: 10985248
[TBL] [Abstract][Full Text] [Related]
18. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
19. A sensitive HIV-1 envelope induced fusion assay identifies fusion enhancement of thrombin.
Cheng DC; Zhong GC; Su JX; Liu YH; Li Y; Wang JY; Hattori T; Ling H; Zhang FM
Biochem Biophys Res Commun; 2010 Jan; 391(4):1780-4. PubMed ID: 20045672
[TBL] [Abstract][Full Text] [Related]
20. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
